- felodipine
-
- $0.00 / 1kg
-
2023-10-10
- CAS:72509-76-3
- Min. Order: 1kg
- Purity: 0.99
- Supply Ability: 20tons
- Felodipine
-
- $0.00 / 25KG
-
2023-09-06
- CAS:72509-76-3
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 50000KG/month
- Felodipine
-
- $200.00 / 1kg
-
2023-06-26
- CAS:72509-76-3
- Min. Order: 10kg
- Purity: 99%
- Supply Ability: 500kg/month
|
| | Felodipine Basic information |
| | Felodipine Chemical Properties |
| Melting point | 142-145°C | | Boiling point | 471.5±45.0 °C(Predicted) | | density | 1.3506 (rough estimate) | | refractive index | 1.6500 (estimate) | | storage temp. | 2-8°C | | solubility | DMSO: 28 mg/mL | | form | solid | | pka | 2.73±0.70(Predicted) | | color | light yellow | | Water Solubility | insoluble | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months. | | InChI | InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3 | | InChIKey | RZTAMFZIAATZDJ-UHFFFAOYSA-N | | SMILES | C1(C)NC(C)=C(C(OC)=O)C(C2=CC=CC(Cl)=C2Cl)C=1C(OCC)=O | | CAS DataBase Reference | 72509-76-3(CAS DataBase Reference) | | NIST Chemistry Reference | Felodipine(72509-76-3) |
| Hazard Codes | Xn | | Risk Statements | 22 | | Safety Statements | 36 | | RIDADR | UN 3077 9 / PGIII | | WGK Germany | 3 | | RTECS | US7968700 | | HS Code | 29333990 |
| | Felodipine Usage And Synthesis |
| Description | Felodipine is a vasodilatory calcium antagonist with a high degree of vascular selectivity.
It is currently indicated for use only in hypertension, either as monotherapy or in
conjunction with diuretics or beta blockers. | | Chemical Properties | White or Light Yellow Crystalline Powder | | Originator | Astra (Sweden) | | Uses | Zanarnivir influenza prophylaxis and therapy | | Uses | vasodilator, Ca channel blocker | | Uses | Felodipine is used as a dihydropyridine calcium channel blocker. It displays high vascular selectivity; lowers arterial blood pressure without altering cardiac contractility. Antihypertensive. | | Definition | ChEBI: The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth m
scle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris. | | Manufacturing Process | Preparation of 2,3-dichlorobenzylideneacetylacetic acid-methylester.
2,3-Dichlorobenzaldehyde is reacted with methyl acetoacetate in a suitable
solvent in the presence of a catalytic amount of acetic acid and piperidine.
Water is azeotropically separated off during the reaction. The reaction mixture
is extracted in order to remove the catalysts. The solvent is evaporated and
methanol is added. The product is crystallized by cooling the solution, isolated
by filtration and finally washed with methanol.
| | Brand name | Plendil (AstraZeneca). | | Therapeutic Function | Antihypertensive | | General Description | Felodipine, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethylmethyl ester (Plendil), is a second-generation dihydropyridinechannel blocker of the nifedipine type. It is more selectivefor vascular smooth muscle than for myocardial tissueand serves as an effective vasodilator. | | Biological Activity | L-type Ca 2+ channel blocker that is selective over N-, R-, P/Q- and T-type channels. Displays high vascular selectivity; lowers arterial blood pressure without altering cardiac contractility. Antihypertensive. | | Clinical Use | Felodipine is used inthe treatment of angina and mild-to-moderate essential hypertension.Felodipine, like most of the dihydropyridines,exhibits a high degree of protein binding and has a half-liferanging from 10 to 18 hours. | | storage | +4°C | | References | 1) Todd and Faulds, (1992)?Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders; Drugs?44?251
2) Furukawa?et al. (1999)?Selectivities of Dihydropyridine Derivatives in Blocking Ca2+ Channel Subtypes Expressed in Xenopus Oocytes; J. Pharmacol. Exp. Ther.?291?464 |
| | Felodipine Preparation Products And Raw materials |
|